Abstract
PURPOSE Studies examining the association between use of oseltamivir and neuropsychiatric events (including suicide) among children have had mixed findings and have been limited by small sample size, reliance on older data, and potential confounding. We undertook an analysis that addresses these limitations.
METHODS Using a national administrative claims database and a case-crossover design that minimized confounding, we analyzed data from 5 contemporary influenza seasons (2009–2013) for individuals aged 1 to 18 years and ascertained oseltamivir exposure from pharmacy dispensing.
RESULTS We identified 21,407 suicide-related events during this study period, 251 of which were in oseltamivir-exposed children. In case-crossover analysis, we did not find any significant association with suicide either for oseltamivir exposure (odds ratio = 0.64; 95% CI, 0.39–1.00; P = .05) or for influenza diagnosis alone (odds ratio = 0.63; 95% CI, 0.34–1.08; P = .10).
CONCLUSION Our findings suggest that oseltamivir does not increase risk of suicide in the pediatric population.
Footnotes
Conflicts of interest: authors report none.
Funding support: Rachel Harrington was supported by NCI training grant 5R25-CA057699. The Department of Pharmacy Systems, Outcomes and Policy and the Center for Pharmacoepidemiology and Pharmacoeconomic Research at the University of Illinois at Chicago, Chicago, Illinois, provided access to the Truven Health Marketscan Commercial Database used in this study.
- Received for publication June 29, 2017.
- Revision received September 20, 2017.
- Accepted for publication October 4, 2017.
- © 2018 Annals of Family Medicine, Inc.